-
Correction: Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness (Clinical Pharmacokinetics, (2026), 10.1007/s40262-025-01610-4)
Wang, Y., Bukkems, L. H., ter Heine, R., van Hasselt, J. G. C., Koolen, S. L. W., Hendrikx, J. J. M. A., van der Hulle, T., Kapiteijn, E., Zwaveling, J., Becker, A., van den Heuvel, M. M., Theelen, W. S. M. E., Oude Munnink, T. H., Smit, E. F., Guchelaar, H.-J. & Moes, D. J. A. R., 1 Apr 2026, In: Clinical Pharmacokinetics. 65, 4, p. 633 1 p.Research output: Contribution to journal › Comment/Letter to the editor › Academic
-
Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness
Wang, Y., Bukkems, L. H., ter Heine, R., van Hasselt, J. G. C., Koolen, S. L. W., Hendrikx, J. J. M. A., van der Hulle, T., Kapiteijn, E., Zwaveling, J., Becker, A., van den Heuvel, M. M., Theelen, W. S. M. E., Oude Munnink, T. H., Smit, E. F., Guchelaar, H.-J. & Moes, D. J. A. R., 1 Apr 2026, In: Clinical Pharmacokinetics. 65, 4, p. 621-632 12 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study
van der Wel, J. W. T., Ernst, S. M., Jebbink, M., van den Broek, D., Badrising, S. K., Steinbusch, L. C., Ruiter, G., Theelen, W. S. M. E., van Veggel, B. A. M. H., Smit, J., Dingemans, A. M., Paats, M. S., Dubbink, H. J., Hashemi, S. M. S., Radonic, T., Cohen, D., van der Wekken, A. J., ter Elst, A., Timens, W. & Hendriks, L. E. & 9 others, , 1 Nov 2025, In: Lung Cancer. 209, 108783.Research output: Contribution to journal › Article › Academic › peer-review
- All publications
